The lipid story in chronic kidney disease: A long story with a happy end?

International Urology and Nephrology

Volumn 45, Issue 5, 2013, Pages 1273-1287

  Kujawa Szewieczek, Agata ^a   Więcek, Andrzej ^a   Piecha, Grzegorz ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Cardiovascular disease; Chronic kidney disease; Dyslipidemia; Statins

Indexed keywords

CHOLESTEROL ACYLTRANSFERASE; DOXORUBICIN; EZETIMIBE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PUROMYCIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; DIALYSIS; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HEMODIALYSIS PATIENT; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MORBIDITY; NEPHROTIC SYNDROME; PERCUTANEOUS CORONARY INTERVENTION; PERITONEAL DIALYSIS; RENAL PROTECTION; RISK FACTOR; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL;

CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NEPHROTIC SYNDROME; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84887065371     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-012-0296-8     Document Type: Article

References (107)

1. Sarnak MJ, Levey AS, Schoolwerth AC et al (2003) Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108:2154-2169
2. Go AS, Chertow GM, Fan D et al (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296-1305
3. Shulman NB, Ford CE, Hall WD et al (1989) Prognostic value of serum creatinine and effect of treatment of hypertension on renal function: results from the hypertension detection and follow-up program. Hypertension 13:80-93
4. Muntner P, Hamm LL, Kusek JW et al (2004) The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 140:9-17
5. Baigent C, Keech A, Kearney PM et al (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267-1278
6. Tonelli M, Isles C, Curhan GC et al (2004) Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 110:1557-1563
7. Tonelli M, Keech A, Shepherd J et al (2005) Effect of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol 16:3748-3754
8. Sever PS, Dahlöf B, Poulter NR et al (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361:1149-1158
9. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7-22
10. Szummer K, Lundman P, Jacobson SH et al (2011) Association between statin treatment and outcome in relation to renal function in survivors of myocardial infarction. Kidney Int 79:997-1004
11. Kendrick J, Shlipak MG, Targher G et al (2010) Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study. Am J Kidney Dis 55:42-49
12. Colhoun HM, Betteridge DJ, Durrington PN et al (2009) Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis 54:810-819
13. Ridker PM, MacFadyen J, Cressman M et al (2010) Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the use of statins in prevention-an intervention trial evaluating rosuvastatin) trial. J Am Coll Cardiol 55:1266-1273
14. Holdaas H, Wanner C, Abletshauser C et al (2007) The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trials. Int J Cardiol 117:64-74
15. Baigent C, Blackwell L, Emberson J et al (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376:1670-1681
16. Holdaas H, Fellström B, Cole E et al (2005) Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant 5:2929-2936
17. Holdaas H, Fellström B, Jardine AG et al (2005) Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation. Nephrol Dial Transplant 20:974-980
18. Wiesbauer F, Heinze G, Mitterbauer C et al (2008) Statin use is associated with prolonged survival of renal transplant recipients. J Am Soc Nephrol 19:2211-2218
19. Baigent C, Landray MJ, Reith C et al (2011) The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377:2181-2192
20. EBPG Expert Group on Renal Transplantation (2002) European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. IV.5.3. Cardiovascular risks. Hyperlipidaemia. Nephrol Dial Transplant 17:26-28
21. Kidney Disease Outcomes Quality Initiative (K/DOQI) Group (2003) K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 41:1-91
22. Chmielewski M, Carrero JJ, Nordfors L et al (2008) Lipid disorders in chronic kidney disease: reverse epidemiology and therapeutic approach. J Nephrol 21:635-644
23. Attman PO, Knight-Gibson C, Tavella M et al (1998) The compositional abnormalities of lipoproteins in diabetic renal failure. Nephrol Dial Transplant 13:2833-2841
24. Hirano T, Sakaue T, Misaki A et al (2003) Very low-density lipoprotein-apoprotein CI is increased in diabetic nephropathy: comparison with apoprotein CIII. Kidney Int 63:2171-2177
25. Nishizawa Y, Shoji T, Kawagishi T et al (1997) Atherosclerosis in uremia: possible roles of hyperparathyroidism and intermediate density lipoprotein accumulation. Kidney Int Suppl 62:90-92
26. Arnadottir M, Nilsson-Ehle P (1995) Has parathyroid hormone any influence on lipid metabolism in chronic renal failure? Nephrol Dial Transplant 10:2381-2382
27. Vaziri ND, Liang K (1997) Down-regulation of VLDL receptor expression in chronic experimental renal failure. Kidney Int 51:913-919
28. Kim C, Vaziri ND (2005) Down-regulation of hepatic LDL receptor-related protein (LRP) in chronic renal failure. Kidney Int 67:1028-1032
29. Heeringa P, Tervaert JW (2002) Role of oxidized low-density lipoprotein in renal disease. Curr Opin Nephrol Hypertens 11:287-293
30. Kasahara J, Kobayashi K, Maeshima Y et al (2004) Clinical significance of serum oxidized low-density lipoprotein/beta2-glycoprotein I complexes in patients with chronic renal diseases. Nephron Clin Pract 98:15-24
31. Deighan CJ, Caslake MJ, McConnell M et al (2000) Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. Am J Kidney Dis 35:852-862
32. O'Neal D, Lee P, Murphy B et al (1996) Low-density lipoprotein particle size distribution in end-stage renal disease treated with hemodialysis or peritoneal dialysis. Am J Kidney Dis 27:84-91
33. Guarnieri GF, Moracchiello M, Campanacci L et al (1978) Lecithin-cholesterol acyltransferase (LCAT) activity in chronic uremia. Kidney Int Suppl 8:26-30
34. McLeod R, Reeve CE, Frohlich J (1984) Plasma lipoproteins and lecithin:cholesterol acyltransferase distribution in patients on dialysis. Kidney Int 25:683-688
35. Vaziri ND (2006) Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 290:262-272
36. Vaziri ND, Deng G, Liang K (1999) Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure. Nephrol Dial Transplantc 14:1462-1466
37. Joven J, Villabona C, Vilella E et al (1990) Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engl J Med 323:579-584
38. Vaziri ND, Sato T, Liang K (2003) Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis. Kidney Int 63:1756-1763
39. Vaziri ND (2003) Molecular mechanisms of lipid disorders in nephrotic syndrome. Kidney Int 63:1964-1976
40. Kashyap ML, Srivastava LS, Hynd BA et al (1980) Apolipoprotein CII and lipoprotein lipase in human nephrotic syndrome. Atherosclerosis 35:29-40
41. Vaziri ND, Kim CH, Phan D et al (2004) Up-regulation of hepatic Acyl CoA: diacylglycerol acyltransferase-1 (DGAT-1) expression in nephrotic syndrome. Kidney Int 66:262-267
42. Ohta T, Matsuda I (1981) Lipid and apolipoprotein levels in patients with nephrotic syndrome. Clin Chim Acta 117:133-143
43. Alexander JH, Schapel GJ, Edwards KD (1974) Increased incidence of coronary heart disease associated with combined elevation of serum triglyceride and cholesterol concentrations in the nephrotic syndrome in man. Med J Aust 2:119-122
44. Joven J, Rubiés-Prat J, Espinel E et al (1987) High-density lipoproteins in untreated idiopathic nephrotic syndrome without renal failure. Nephrol Dial Transplant 2:149-153
45. Cheung AK, Wu LL, Kablitz C et al (1993) Atherogenic lipids and lipoproteins in hemodialysis patients. Am J Kidney Dis 22:271-276
46. Rapoport J, Aviram M, Chaimovitz C et al (1978) Defective high-density lipoprotein composition in patients on chronic hemodialysis. A possible mechanism for accelerated atherosclerosis. N Engl J Med 299:1326-1329
47. Attman PO, Alaupovic P (1991) Lipid and apolipoprotein profiles of uremic dyslipoproteinemia-relation to renal function and dialysis. Nephron 57:401-410
48. Näsström B, Stegmayr B, Olivecrona G et al (2004) Lipoprotein lipase in hemodialysis patients: indications that low molecular weight heparin depletes functional stores, despite low plasma levels of the enzyme. BMC Nephrol 5:17
49. Blankestijn PJ, Vos PF, Rabelink TJ et al (1995) High-flux dialysis membranes improve lipid profile in chronic hemodialysis patients. J Am Soc Nephrol 5:1703-1708
50. Attman PO, Samuelsson OG, Moberly J et al (1999) Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis. Kidney Int 55:1536-1542
51. Kronenberg F, Lingenhel A, Neyer U et al (2003) Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients. Kidney Int Suppl 84:113-116
52. Kronenberg F, König P, Neyer U et al (1995) Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 6:110-120
53. Johansson AC, Samuelsson O, Attman PO et al (2000) Dyslipidemia in peritoneal dialysis-relation to dialytic variables. Perit Dial Int 20:306-314
54. Prinsen BH, Rabelink TJ, Romijn JA et al (2004) A broad-based metabolic approach to study VLDL apoB100 metabolism in patients with ESRD and patients treated with peritoneal dialysis. Kidney Int 65:1064-1075
55. Steele J, Billington T, Janus E et al (1989) Lipids, lipoproteins and apolipoproteins A-I and B and apolipoprotein losses in continuous ambulatory peritoneal dialysis. Atherosclerosis 79:47-50
56. Foley RN, Parfrey PS, Sarnak MJ (1998) Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32:112-119
57. Sarnak MJ, Coronado BE, Greene T et al (2002) Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol 5:327-335
58. Coresh J, Longenecker JC, Miller ER III et al (1998) Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol 9:24-30
59. Kronenberg F, Kuen E, Ritz E et al (2000) Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol 11:105-115
60. Kronenberg F, Neyer U, Lhotta K et al (1999) The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. J Am Soc Nephrol 10:1027-1036
61. Berlyne GM, Mallick NP (1969) Ischaemic heart-disease as a complication of nephrotic syndrome. Lancet 2:399-400
62. Wass V, Cameron JS (1981) Cardiovascular disease and the nephrotic syndrome: the other side of the coin. Nephron 27:58-61
63. Ordoñez JD, Hiatt RA, Killebrew EJ et al (1993) The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 44:638-642
64. Lechner BL, Bockenhauer D, Iragorri S et al (2004) The risk of cardiovascular disease in adults who have had childhood nephrotic syndrome. Pediatr Nephrol 19:744-748
65. Cheung AK, Sarnak MJ, Yan G et al (2000) Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 58:353-362
66. Cressman MD, Heyka RJ, Paganini EP et al (1992) Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 86:475-482
67. Hahn R, Oette K, Mondorf H et al (1983) Analysis of cardiovascular risk factors in chronic hemodialysis patients with special attention to the hyperlipoproteinemias. Atherosclerosis 48:279-288
68. Iseki K, Yamazato M, Tozawa M et al (2002) Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 61:1887-1893
69. Kalantar-Zadeh K, Kopple JD, Block G et al (2001) A malnutrition- inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients. Am J Kidney Dis 38:1251-1263
70. Kilpatrick RD, McAllister CJ, Kovesdy CP et al (2007) Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol 18:293-303
71. Lowrie EG, Lew NL (1990) Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15:458-482
72. Liu Y, Coresh J, Eustace JA et al (2004) Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 291:451-459
73. Koda Y, Nishi S, Suzuki M et al (1999) Lipoprotein(a) is a predictor for cardiovascular mortality of hemodialysis patients. Kidney Int Suppl 71:251-253
74. Webb AT, Brown EA (1993) Prevalence of symptomatic arterial disease and risk factors for its development in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 13:406-408
75. Olivares J, Cruz C, Gas JM et al (1992) Evolution of lipid profiles in long-term peritoneal dialysis. Adv Perit Dial 8:373-375
76. Gault MH, Longerich L, Prabhakaran V et al (1991) Ischemic heart disease, serum cholesterol, and apolipoproteins in CAPD. ASAIO Trans 37:513-514
77. Piccoli GB, Quarello F, Salomone M et al (1995) Are serum albumin and cholesterol reliable outcome markers in elderly dialysis patients? Nephrol Dial Transplant 10:72-77
78. Sreedhara R, Avram MM, Blanco M et al (1996) Prealbumin is the best nutritional predictor of survival in hemodialysis and peritoneal dialysis. Am J Kidney Dis 28:937-942
79. Iliescu EA, Marcovina SM, Morton AR et al (2002) Apolipoprotein(a) phenotype and lipoprotein(a) level predict peritoneal dialysis patient mortality. Perit Dial Int 22:492-499
80. Moorhead JF, Chan MK, El-Nahas M et al (1982) Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 2:1309-1311
81. Galle J, Heermeier K, Wanner C (1999) Atherogenic lipoproteins, oxidative stress, and cell death. Kidney Int Suppl 71:62-65
82. Bussolati B, Deregibus MC, Fonsato V et al (2005) Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase/AKT-signaling pathway. J Am Soc Nephrol 16:1936-1947
83. Gyebi L, Soltani Z, Reisin E (2012) Lipid Nephrotoxicity: new concept for an old disease. Curr Hypertens Rep 14:177-181
84. Attman PO, Alaupovic P, Samuelsson O (1999) Lipoprotein abnormalities as a risk factor for progressive nondiabetic renal disease. Kidney Int Suppl 71:14-17
85. Asselbergs FW, Diercks GF, Hillege HL et al (2004) Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 110:2809-2816
86. Brouwers FP, Asselbergs FW, Hillege HL et al (2011) Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria: ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT). Am Heart J 161:1171-1178
87. Navaneethan SD, Pansini F, Perkovic V et al (2009) HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2:7784
88. Holdaas H, Fellström B, Jardine AG et al (2003) Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 361:2024-2031
89. Tonelli M, Collins D, Robins S et al (2004) Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. Kidney Int 66:1123-1130
90. Cormack-Aboud FC, Brinkkoetter PT, Pippin JW et al (2009) Rosuvastatin protects against podocyte apoptosis in vitro. Nephrol Dial Transplant 24:404-412
91. Sakurai N, Kuroiwa T, Ikeuchi H et al (2009) Fluvastatin prevents podocyte injury in a murine model of HIV-associated nephropathy. Nephrol Dial Transplant 24:2378-2383
92. Athyros VG, Mikhailidis DP, Papageorgiou AA et al (2004) The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 57:728-734
93. Shepherd J, Kastelein JJ, Bittner V et al (2007) Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol 2:1131-1139
94. Tonelli M, Isles C, Craven T et al (2005) Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 112:171-178
95. Sandhu S, Wiebe N, Fried LF et al (2006) Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 17:2006-2016
96. Abe M, Maruyama N, Yoshida Y et al (2011) Efficacy analysis of the lipid-lowering and renoprotective effects of rosuvastatin in patients with chronic kidney disease. Endocr J 58:663-674
97. Bianchi S, Bigazzi R, Caiazza A et al (2003) A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 41:565-570
98. Seliger SL, Weiss NS, Gillen DL et al (2002) HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 61:297-304
99. Mason NA, Bailie GR, Satayathum S et al (2005) HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis 45:119-126
100. Lee JE, Oh KH, Choi KH et al (2011) Statin therapy is associated with improved survival in incident peritoneal dialysis patients: propensity-matched comparison. Nephrol Dial Transplant 26:4090-4094
101. Wanner C, Krane V, März W et al (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353:238-248
102. Fellström BC, Jardine AG, Schmieder RE et al (2009) Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360:1395-1407
103. Holdaas H, Holme I, Schmieder RE et al (2011) Rosuvastatin in diabetic hemodialysis patients. J Am Soc Nephrol 22:1335-1341
104. Zoccali C (2000) Cardiovascular risk in uraemic patients - is it fully explained by classical risk factors? Nephrol Dial Transplant 15:454-457
105. Amann K, Tyralla K, Gross ML et al (2003) Special characteristics of atherosclerosis in chronic renal failure. Clin Nephrol 60:13-21
106. London GM, Guérin AP, Marchais SJ et al (2003) Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18:1731-1740
107. Kanbay M, Afsar B, Goldsmith D et al (2010) Sudden death in hemodialysis: an update. Blood Purif 30:135-145